Robert A. Figlin (Hrsg.)

Gebundenes Buch

Kidney Cancer

Beschreibung

Kidney cancer is a heterogenous disease. This book covers:

-new surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques;
-new staging and prognostic capabilities;
-evolving therapeutic options include, cell based vaccine, gene and antibody therapy;
-molecular genetics allow for a better understanding of the various types of kidney cancer.

Kidney Cancer is a comprehensive review covering present and future surgical approaches, staging and prognostic factors, currently accepted and future plans for prevention, diagnosis and treatment. Contributing authors to this book are internationally recognized specialists in this disease. This book will be useful to the specialist (oncologist and urologist), primary care physicians, patients and family members dealing with kidney cancer.

Autor

Robert A. Figlin, Professor of Medicine, Urology, Departments of Medicine and Urology, Division of Hematology/Oncology, University of California, Los Angeles School of Medicine, USA, holds the Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology. He serves as Medical Director of the Thoracic and Genitourinary Oncology Program. He is a Senior Clinical Investigator in areas of genitourinary and thoracic oncology and has served as Principal Investigator on Phase I, II, and III trials. He serves as Chairman of the UCLA Medical Institutional Review Board and as a member of the UCLA Human Research Policy Board.

Produktdetails

• Cancer Treatment and Research 116
• Verlag: Springer / Springer US / Springer, Berlin
• Artikelnr. des Verlages: 978-1-4020-7457-8
• 2003
• Seitenzahl: 260
• Erscheinungstermin: 31. Oktober 2003
• Englisch
• Abmessung: 241mm x 160mm x 19mm
• Gewicht: 544g
• ISBN-13: 9781402074578
• ISBN-10: 1402074573
• Artikelnr.: 21062211

Rezensionen

"This text provides a comprehensive overview of kidney cancer. Investigative leaders in the field discuss the genetic, biologic and clinical manifestations of the disease. Modern therapy is reviewed with commentary on future alternatives and novel compounds."
(Steven T. Rosen, M.D., Series Editor)